Alza: Difference between revisions
CSV import |
CSV import |
||
| Line 3: | Line 3: | ||
File:Alza_pano_from_Permanente_Creek_Trail.jpg | File:Alza_pano_from_Permanente_Creek_Trail.jpg | ||
</gallery> | </gallery> | ||
== Alza Corporation == | |||
'''Alza Corporation''' was a pharmaceutical and medical systems company known for its development of drug delivery systems. Founded in 1968 by Dr. Alejandro Zaffaroni, Alza was a pioneer in the field of controlled drug delivery, which involves the release of medication into the body in a controlled manner over time. | |||
=== History === | |||
Alza Corporation was established in Palo Alto, California, with the aim of developing innovative drug delivery technologies. The company was named after its founder, Alejandro Zaffaroni, who was a prominent figure in the biotechnology industry. Alza's early work focused on transdermal patches and other delivery systems that could improve the efficacy and safety of pharmaceuticals. | |||
In 2001, Alza was acquired by [[Johnson & Johnson]], a major healthcare company, and became part of its pharmaceutical division. This acquisition allowed Alza to expand its research and development capabilities and integrate its technologies into a broader range of products. | |||
=== Drug Delivery Technologies === | |||
Alza Corporation was renowned for its development of several key drug delivery technologies, including: | |||
* '''Transdermal Patches''': Alza was a leader in the development of transdermal drug delivery systems, which allow drugs to be absorbed through the skin. This method is used for medications such as nicotine patches for smoking cessation and hormone replacement therapy. | |||
* '''Osmotic Controlled Release Oral Delivery System (OROS)''': This technology uses osmotic pressure to deliver drugs at a controlled rate. It is used in medications such as [[Concerta]], a treatment for [[Attention Deficit Hyperactivity Disorder (ADHD)]]. | |||
* '''Doxil''': Alza developed Doxil, a liposomal formulation of the chemotherapy drug doxorubicin, which is used to treat certain types of cancer. The liposomal delivery system helps to reduce the side effects of the drug by targeting cancer cells more effectively. | |||
=== Impact on the Pharmaceutical Industry === | |||
Alza's innovations in drug delivery have had a significant impact on the pharmaceutical industry. By improving the delivery and efficacy of medications, Alza's technologies have enhanced patient compliance and outcomes. The company's work has paved the way for further advancements in the field of drug delivery, influencing the development of new therapies and treatment modalities. | |||
=== Acquisition and Legacy === | |||
After its acquisition by [[Johnson & Johnson]], Alza continued to operate as a subsidiary, contributing to the development of new drug delivery systems and products. Although Alza as a standalone company no longer exists, its legacy lives on through the technologies it developed and the impact it had on the pharmaceutical industry. | |||
== Related Pages == | |||
* [[Johnson & Johnson]] | |||
* [[Drug delivery]] | |||
* [[Transdermal patch]] | |||
* [[Controlled release]] | |||
* [[Biotechnology]] | |||
{{Johnson & Johnson}} | |||
[[Category:Pharmaceutical companies of the United States]] | |||
[[Category:Biotechnology companies]] | |||
[[Category:Companies established in 1968]] | |||
[[Category:Companies disestablished in 2001]] | |||
Latest revision as of 00:38, 19 February 2025
Alza Corporation[edit]
Alza Corporation was a pharmaceutical and medical systems company known for its development of drug delivery systems. Founded in 1968 by Dr. Alejandro Zaffaroni, Alza was a pioneer in the field of controlled drug delivery, which involves the release of medication into the body in a controlled manner over time.
History[edit]
Alza Corporation was established in Palo Alto, California, with the aim of developing innovative drug delivery technologies. The company was named after its founder, Alejandro Zaffaroni, who was a prominent figure in the biotechnology industry. Alza's early work focused on transdermal patches and other delivery systems that could improve the efficacy and safety of pharmaceuticals.
In 2001, Alza was acquired by Johnson & Johnson, a major healthcare company, and became part of its pharmaceutical division. This acquisition allowed Alza to expand its research and development capabilities and integrate its technologies into a broader range of products.
Drug Delivery Technologies[edit]
Alza Corporation was renowned for its development of several key drug delivery technologies, including:
- Transdermal Patches: Alza was a leader in the development of transdermal drug delivery systems, which allow drugs to be absorbed through the skin. This method is used for medications such as nicotine patches for smoking cessation and hormone replacement therapy.
- Osmotic Controlled Release Oral Delivery System (OROS): This technology uses osmotic pressure to deliver drugs at a controlled rate. It is used in medications such as Concerta, a treatment for Attention Deficit Hyperactivity Disorder (ADHD).
- Doxil: Alza developed Doxil, a liposomal formulation of the chemotherapy drug doxorubicin, which is used to treat certain types of cancer. The liposomal delivery system helps to reduce the side effects of the drug by targeting cancer cells more effectively.
Impact on the Pharmaceutical Industry[edit]
Alza's innovations in drug delivery have had a significant impact on the pharmaceutical industry. By improving the delivery and efficacy of medications, Alza's technologies have enhanced patient compliance and outcomes. The company's work has paved the way for further advancements in the field of drug delivery, influencing the development of new therapies and treatment modalities.
Acquisition and Legacy[edit]
After its acquisition by Johnson & Johnson, Alza continued to operate as a subsidiary, contributing to the development of new drug delivery systems and products. Although Alza as a standalone company no longer exists, its legacy lives on through the technologies it developed and the impact it had on the pharmaceutical industry.
Related Pages[edit]
